Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Negocios · 26/7/20221 min de lectura
Revocation of Emergency Use of a Drug During the COVID-19 Pandemic; Availability
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Gilead Sciences, Inc. (Gilead) for VEKLURY (remdesivir). FDA revoked the Authorization on April 25, 2022, under the Federal Food, Drug, and Cosmetic Act (FD&C Act) given the approval of a supplemental new drug application (NDA) for VEKLURY, which expanded the approved indication to cover the authorized population. The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.
Idioma original de la fuente: Federal Register — Food and Drug AdministrationAbrir el comunicado original →